PuraCap International

PuraCap International is a commercial-stage pharmaceutical company focused on prescription generics, OTC products, private-label products, manufacturing, and distribution. The company was created in 2016 as part of PuraCap Pharmaceutical's acquisition of Blu Pharmaceutical and Blu Caribe, forming PuraCap International LLC as a joint venture with Dangdai International Group. Its operating footprint has included generic drug development and marketing through PuraCap Laboratories and manufacturing through affiliated operations in Dorado, Puerto Rico. Publicly visible product offerings are marketed generics rather than a clinical R&D pipeline, with examples including azithromycin, doxycycline, gemfibrozil, simvastatin, sulindac, ursodiol, and flavoxate products. The business appears oriented toward affordable established medicines, oral solid dosage manufacturing, supply, and commercialization rather than novel therapeutics discovery.